Japan's Meiji Seika Pharma has decided to establish a local subsidiary in Singapore to strengthen its presence and expand its business in the ASEAN region through the commercialisation, marketing and distribution of pharmaceuticals, including vaccines. The new subsidiary is expected to begin operations around spring 2026.
Under the "Meiji Group 2026 Vision," Meiji Seika Pharma aims to become "a leading company in Asia in the field of infectious diseases". Through establishing its Singapore base, Meiji Seika Pharma intends to reliably supply essential products and contribute to the health and well-being of the people in the region.
